YPH Stock Overview Manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Astellas Pharma Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Astellas Pharma Historical stock prices Current Share Price JP¥9.17 52 Week High JP¥11.70 52 Week Low JP¥8.47 Beta 0.23 1 Month Change -3.45% 3 Month Change -13.10% 1 Year Change -12.69% 3 Year Change -34.49% 5 Year Change -39.56% Change since IPO 51.25%
Recent News & Updates
Second quarter 2025 earnings released: EPS: JP¥20.06 (vs JP¥1.50 in 2Q 2024) Oct 31
Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer Oct 19 Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 05
Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 04
Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer Sep 24
Upcoming dividend of JP¥37.00 per share Sep 20 See more updates
Second quarter 2025 earnings released: EPS: JP¥20.06 (vs JP¥1.50 in 2Q 2024) Oct 31
Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer Oct 19 Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 05
Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024 Oct 04
Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer Sep 24
Upcoming dividend of JP¥37.00 per share Sep 20
Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society Sep 04
European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer Aug 28
Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy Aug 27
Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer Aug 20
First quarter 2025 earnings released: EPS: JP¥21.00 (vs JP¥18.46 in 1Q 2024) Aug 02 Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
Final dividend of JP¥37.00 announced Jul 11
Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024 Jun 29
Full year 2024 earnings released: EPS: JP¥9.51 (vs JP¥54.24 in FY 2023) Jun 25 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date May 31
Full year 2024 earnings released: EPS: JP¥9.51 (vs JP¥54.24 in FY 2023) Apr 26 Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting Apr 25 Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024
Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024 Apr 03
U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy Apr 02
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Mar 28
Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer Mar 27
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting Mar 22
Upcoming dividend of JP¥35.00 per share Mar 21
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan Mar 05
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA Feb 16
Third quarter 2024 earnings released: EPS: JP¥10.40 (vs JP¥26.12 in 3Q 2023) Feb 06
New minor risk - Financial position Feb 06
Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer Jan 31 European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Jan 27
Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S Jan 09
Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024 Dec 28
Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children Dec 18 Pfizer Inc. and Astellas Pharma Inc. Announce U.S. Food and Drug Administration Approved PADCEV (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA (pembrolizumab, a PD-1 inhibitor) for the Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC) Dec 16
Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause Dec 11
Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis Dec 09
Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer Dec 02
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy Nov 30 Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Second quarter 2024 earnings released: JP¥0.81 loss per share (vs JP¥39.30 profit in 2Q 2023) Nov 02
Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy Oct 24
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023 Oct 16
Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant) Oct 14
Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023 Sep 28
Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial Sep 23
Upcoming dividend of JP¥35.00 per share at 3.2% yield Sep 21 Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer
Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY Sep 19
European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Sep 13
Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Aug 30
Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503). Aug 29 FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Aug 24
Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol Aug 18
U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children Aug 11
Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials Aug 09 Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023 Aug 03
First quarter 2024 earnings released: EPS: JP¥18.46 (vs JP¥13.60 in 1Q 2023) Aug 02
China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab Aug 01
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab Jul 14
Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023 Jul 12
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application Jul 06
Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for Fezolinetant Jun 28
Full year 2023 earnings released: EPS: JP¥54.24 (vs JP¥67.08 in FY 2022) Jun 28
Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial Jun 12
Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for Zolbetuximab Jun 09
Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to Menopause May 17
Full year 2023 earnings released: EPS: JP¥54.24 (vs JP¥67.08 in FY 2022) Apr 29
Upcoming dividend of JP¥30.00 per share at 3.2% yield Mar 23 Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.S Feb 20
Third quarter 2023 earnings released: EPS: JP¥26.56 (vs JP¥32.86 in 3Q 2022) Feb 08 Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Shareholder Returns YPH DE Pharmaceuticals DE Market 7D -2.0% -2.5% -2.6% 1Y -12.7% -15.6% 6.9%
See full shareholder returns
Return vs Market: YPH underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is YPH's price volatile compared to industry and market? YPH volatility YPH Average Weekly Movement 4.3% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: YPH has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: YPH's weekly volatility (4%) has been stable over the past year.
About the Company Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Show more Astellas Pharma Inc. Fundamentals Summary How do Astellas Pharma's earnings and revenue compare to its market cap? YPH fundamental statistics Market cap €16.92b Earnings (TTM ) €335.56m Revenue (TTM ) €10.86b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) YPH income statement (TTM ) Revenue JP¥1.77t Cost of Revenue JP¥322.95b Gross Profit JP¥1.45t Other Expenses JP¥1.39t Earnings JP¥54.75b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 30.58 Gross Margin 81.78% Net Profit Margin 3.09% Debt/Equity Ratio 61.2%
How did YPH perform over the long term?
See historical performance and comparison Dividends
4.8% Current Dividend Yield When do you need to buy YPH by to receive an upcoming dividend? Astellas Pharma dividend dates Ex Dividend Date Mar 28 2025 Dividend Pay Date Jun 03 2025 Days until Ex dividend 96 days Days until Dividend pay date 163 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 06:28 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Astellas Pharma Inc. is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Atsushi Seki Barclays Koichi Mamegano BofA Global Research Hazim Bahari CFRA Equity Research
Show 28 more analysts 
